Compounds (3,5-Odicaffeoyl-d-quinic acid and matesaponin-2 and linolenic acid exhibited significant elevations in GLP-1 levels [33]
Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not
, , ,
The primary composite endpoint (cardiovascular death or worsening heart failure) was reached in 9,9% of the tirzepatide arm versus 15,3% of the placebo arm (HR 0,62, p=0,026)
At this stage, the most responsible way to phrase the issue is: Retatrutide may become part of a more advanced generation of metabolic medications, but muscle preservation still depends on the full treatment plan including protein intake, resistance training, dose management, nutrition quality, sleep, hormones, and medical monitoring
What gets consumed is different